دورية أكاديمية
أعرض في EDS

The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study.

التفاصيل البيبلوغرافية
العنوان: The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study.
المؤلفون: Netti GS; Unit of Clinical Pathology, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.; Unit of Clinical Pathology, Department of Laboratory Diagnostics, University Hospital 'Policlinico Riuniti', 71122 Foggia, Italy., Soccio P; Unit of Respiratory Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Catalano V; Unit of Clinical Pathology, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., De Luca F; Unit of Clinical Pathology, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Khalid J; Unit of Clinical Pathology, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Camporeale V; Unit of Clinical Pathology, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Moriondo G; Unit of Respiratory Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Papale M; Unit of Clinical Pathology, Department of Laboratory Diagnostics, University Hospital 'Policlinico Riuniti', 71122 Foggia, Italy., Scioscia G; Unit of Respiratory Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Corso G; Unit of Clinical Pathology, Department of Laboratory Diagnostics, University Hospital 'Policlinico Riuniti', 71122 Foggia, Italy.; Clinical Biochemistry, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy., Foschino MP; Unit of Respiratory Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Lo Caputo S; Unit of Infectious Diseases, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Lacedonia D; Unit of Respiratory Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Ranieri E; Unit of Clinical Pathology, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.; Unit of Clinical Pathology, Department of Laboratory Diagnostics, University Hospital 'Policlinico Riuniti', 71122 Foggia, Italy.
المصدر: Biomedicines [Biomedicines] 2024 Jun 13; Vol. 12 (6). Date of Electronic Publication: 2024 Jun 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: The immune system's amplified response to SARS-CoV-2 may lead to the production of autoantibodies, but their specific impact on disease severity and outcome remains unclear. This study aims to assess if hospitalized COVID-19 patients face a worse prognosis based on ANA presence, even without autoimmune diseases. We performed a retrospective, single-center, observational cohort study, enrolling 638 COVID-19 patients hospitalized from April 2020 to March 2021 at Hospital "Policlinico Riuniti" of Foggia (Italy). COVID-19 patients with a positive ANA test exhibited a significantly lower 30-day survival rate (64.4% vs. 83.0%) and a higher likelihood of severe respiratory complications during hospitalization than those with negative ANA screening (35.4% vs. 17.0%) ( p < 0.001). The association between poor prognosis and ANA status was identified by calculating the HALP score (Hemoglobin-Albumin-Lymphocyte-Platelet), which was lower in COVID-19 patients with a positive ANA test compared to ANA-negative patients (108.1 ± 7.4 vs. 218.6 ± 11.2 AU; p < 0.011). In detail, COVID-19 patients with a low HALP showed a lower 30-day survival rate (99.1% vs. 83.6% vs. 55.2% for high, medium, and low HALP, respectively; p < 0.001) and a higher incidence of adverse respiratory events compared to those with high and medium HALP (13.1% vs. 35.2% vs. 64.6% for high, medium, and low HALP, respectively; p < 0.001). In summary, ANA positivity in COVID-19 patients appears to be linked to a more aggressive disease phenotype with a reduced survival rate. Furthermore, we propose that the HALP score could serve as a valuable parameter to assess prognosis for COVID-19 patients.
References: Blood. 2010 Jun 10;115(23):4699-706. (PMID: 20351305)
Science. 2020 Oct 23;370(6515):. (PMID: 32972996)
World J Methodol. 2022 Jul 20;12(4):200-223. (PMID: 36159097)
Am J Emerg Med. 2021 Oct;48:140-147. (PMID: 33895645)
Clin Rheumatol. 2020 Sep;39(9):2811-2815. (PMID: 32720260)
Oncotarget. 2023 Feb 25;14:153-172. (PMID: 36848404)
Transpl Immunol. 2023 Jun;78:101791. (PMID: 36682573)
Autoimmun Rev. 2021 Mar;20(3):102754. (PMID: 33476817)
Crit Care. 2020 May 26;24(1):255. (PMID: 32456658)
Bosn J Basic Med Sci. 2021 Dec 01;21(6):773-781. (PMID: 33974528)
J Inflamm Res. 2023 May 22;16:2173-2188. (PMID: 37250104)
J Immunol Res. 2019 Nov 5;2019:8483650. (PMID: 31781684)
Clin Transl Sci. 2021 Sep;14(5):1625-1626. (PMID: 33934534)
Emerg Microbes Infect. 2020 Dec;9(1):727-732. (PMID: 32196410)
Int Immunopharmacol. 2023 Jan;114:109496. (PMID: 36462339)
Autoimmun Rev. 2020 Dec;19(12):102695. (PMID: 33130000)
Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F723-F731. (PMID: 30672713)
Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(7):717-30. (PMID: 20689230)
Clin Transl Sci. 2021 Sep;14(5):1627-1628. (PMID: 33932091)
Autoimmun Rev. 2020 Aug;19(8):102597. (PMID: 32535093)
N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
Clin Kidney J. 2020 Feb 10;13(3):450-460. (PMID: 32699626)
J Transl Autoimmun. 2020;3:100073. (PMID: 33263103)
BMC Urol. 2018 Mar 15;18(1):20. (PMID: 29544476)
Auto Immun Highlights. 2016 Dec;7(1):1. (PMID: 26831867)
Rheumatol Int. 2020 Oct;40(10):1539-1554. (PMID: 32666137)
World J Gastroenterol. 2020 Feb 28;26(8):828-838. (PMID: 32148380)
Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):357-68. (PMID: 12220549)
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295. (PMID: 25190079)
Mol Immunol. 2021 Sep;137:105-113. (PMID: 34242919)
Front Med (Lausanne). 2021 Aug 25;8:709402. (PMID: 34513877)
Nutr Diabetes. 2021 Jun 23;11(1):19. (PMID: 34168111)
J Thromb Haemost. 2020 Jun;18(6):1469-1472. (PMID: 32302435)
Pathog Immun. 2021 Mar 8;6(1):31-54. (PMID: 33969248)
Clin Transl Sci. 2021 Mar;14(2):502-508. (PMID: 32989903)
Intensive Care Med. 2020 May;46(5):846-848. (PMID: 32125452)
Nat Immunol. 2020 Dec;21(12):1506-1516. (PMID: 33028979)
Clin Rheumatol. 2020 Jul;39(7):2095-2097. (PMID: 32462425)
J Clin Med. 2020 Jul 29;9(8):. (PMID: 32751400)
Infect Drug Resist. 2023 Jul 11;16:4505-4518. (PMID: 37457796)
Front Med (Lausanne). 2020 Jun 26;7:357. (PMID: 32671083)
Korean J Intern Med. 2023 May;38(3):417-426. (PMID: 37016892)
Clin Transl Sci. 2020 Nov;13(6):1077-1086. (PMID: 32315487)
Nat Rev Rheumatol. 2021 Jun;17(6):315-332. (PMID: 33903743)
Front Pharmacol. 2022 Nov 23;13:1033674. (PMID: 36506506)
Antioxid Redox Signal. 2021 Jul 10;35(2):139-142. (PMID: 32524832)
J Hepatocell Carcinoma. 2023 Jun 02;10:821-831. (PMID: 37288141)
Ann Hematol. 2020 Jul;99(7):1421-1428. (PMID: 32495027)
Ann N Y Acad Sci. 2007 Jun;1108:584-93. (PMID: 17894023)
Rev Assoc Med Bras (1992). 2022 Jan;68(1):82-86. (PMID: 34909968)
Ann Rheum Dis. 2021 May;80(5):e73. (PMID: 32753426)
Autoimmun Rev. 2022 Mar;21(3):103012. (PMID: 34896650)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Rev Med Virol. 2020 Nov;30(6):1-9. (PMID: 32845568)
Clin Nutr ESPEN. 2021 Feb;41:423-428. (PMID: 33487301)
J Intensive Care. 2020 May 24;8:36. (PMID: 32483488)
J Exp Med. 2017 Nov 6;214(11):3207-3217. (PMID: 28899868)
Am J Med. 2020 Jun;133(6):713-722.e7. (PMID: 31751531)
N Engl J Med. 2020 Apr 30;382(18):e43. (PMID: 32294340)
Eur Respir J. 2021 Oct 21;58(4):. (PMID: 34244321)
J Immunoassay Immunochem. 2016;37(5):439-52. (PMID: 27050929)
فهرسة مساهمة: Keywords: ANA; COVID-19; HALP score; SARS-CoV-2; antinuclear antibodies
تواريخ الأحداث: Date Created: 20240627 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11201662
DOI: 10.3390/biomedicines12061306
PMID: 38927513
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9059
DOI:10.3390/biomedicines12061306